Sorin aims to become a player in the U.S. medical device market

May 24, 2012 by Brad Perriello

Sorin Group president Stefano Di Lullo tells about the European juggernaut's plans to boost its footprint in the U.S. market for medical devices with its innovative SonR technology.

Sorin Group president Stefano Di Lullo

Sorin Group (BIT:SRN) is an established leader in the cardiac rhythm management space, but in the U.S. it's a back-bencher compared with more established competitors like Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ).

That's all about to change, if Stefano Di Lullo has anything to say about it.

Sign up to get our free newsletters delivered right to your inbox.

Di Lullo, president of Sorin Group, is helping to spearhead the company's push into the U.S. CRM market. Earlier this month he announced the launch here of a complete line of pacemakers and defibrillators, sending a clear signal that Sorin intends to make a run for it in America.

But it's the company's SonR technology that has Di Lullo really excited. SonR uses hemodynamic measurements and a software algorithm to fine-tune cardiac rhythm therapy for each patient's particular condition.

"I really personally believe that it's probably one of the major innovations in this space today," Di Lullo told when we caught up with him at the recent Heart Rhythm Society meeting in Boston.

Di Lullo gave us the background on Sorin's push into the U.S. CRM space and the lowdown on why he believes the SonR technology is a true game-changer.